A Randomized Study of Melphalan 200 mg/m(2) vs 280 mg/m(2) as a Preparative Regimen for Patients with Multiple Myeloma Undergoing Auto-SCT

To examine whether doses of melphalan higher than 200 mg/m(2) improve response rates when used as conditioning before autologous transplant (ASCT) in myeloma (MM) patients. Patients with MM, N= 131, were randomized to 200 mg/m(2) (mel200) v. 280 mg/m(2) (mel280) using amifostine pretreatment. The pr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Bone Marrow Transplant
Main Authors: Bensinger, William I., Becker, Pamela S., Gooley, Ted A., Chauncey, Thomas R., Maloney, David G., Gopal, Ajay K., Green, Damian J., Press, Oliver W., Lill, Michael, Ifthikharuddin, Jainulabdeen J., Vescio, Robert, Holmberg, Leona A., Phillips, Gordon L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4894718/
https://ncbi.nlm.nih.gov/pubmed/26367217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2015.211
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados